000710.SHE Berry Genomics Co Ltd
- Market cap
- CNY 3.18B
- P/E
- -
- P/B
- 2.40x
- ROE
- -10.1%
- Dividend yield
- 0.15%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 000710.SHE undervalued?
Graham numberThe Graham number of Berry Genomics Co Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Berry Genomics Co Ltd fundamental analysis
No fundamental analysis for Berry Genomics Co Ltd yet.
Berry Genomics Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Berry Genomics Co Ltd
Berry Genomics Co.,Ltd, a genomics and life science company, develops and commercializes of genetic test technologies in clinical applications in China. The company offers non-invasive DNA prenatal testing service, genetic disease testing, tumor detection, technology services, equipment/reagents, laboratory overall solution, and big data services. It also offers scientific research services and medical testing services and products. In addition, the company provides GENOSi, …
Full company profileBerry Genomics Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Berry Genomics Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 922M | 1.17B | 1.44B | 1.62B | 1.54B | 1.42B | 1.37B | 1.15B | 1.08B | 930M | 902M |
| Gross Profit | 565M | 700M | 820M | 964M | 779M | 594M | 546M | 483M | 474M | 401M | 429M |
| Operating Income | 177M | 275M | 305M | 450M | 245M | -110M | -280M | -451M | -167M | -71.2M | -48.6M |
| EBITDA | 227M | 339M | 380M | 529M | 338M | -1.46M | -167M | -336M | -84.3M | -90.5M | -115M |
| Net Income | 151M | 233M | 268M | 391M | 211M | -111M | -249M | -427M | -192M | -197M | -137M |
| EPS | 0.75 | 0.92 | 0.76 | 1.10 | 0.59 | -0.31 | -0.81 | -1.21 | -0.54 | -0.56 | -0.39 |
| Balance Sheet | |||||||||||
| Total Assets | 548M | 1.81B | 2.18B | 3.07B | 3.24B | 3.52B | 3.20B | 2.74B | 2.38B | 2.28B | 2.12B |
| Total Liabilities | 434M | 246M | 236M | 722M | 822M | 996M | 872M | 847M | 670M | 780M | 745M |
| Shareholders' Equity | 114M | 1.54B | 1.90B | 2.33B | 2.39B | 2.49B | 2.30B | 1.86B | 1.68B | 1.48B | 1.36B |
| Cash & Short-term Investments | 74.0M | 412M | 424M | 418M | 633M | 422M | 338M | 352M | 400M | 380M | 201M |
| Total Debt | 108M | 29.3M | - | 256M | 360M | 399M | 348M | 248M | 157M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -14.2M | 74.4M | 165M | 123M | 161M | 94.0M | 21.2M | 111M | 88.0M | 70.6M | - |
| Capital Expenditure | 57.9M | 205M | 166M | 295M | 113M | 337M | 73.3M | 55.1M | 56.8M | 75.7M | 48.2M |
| Free Cash Flow | -72.1M | -130M | -530K | -172M | 48.8M | -243M | -52.1M | 55.9M | 31.2M | -5.08M | -226M |
| Ratios | |||||||||||
| ROE | 132.4% | 15.1% | 14.1% | 16.8% | 8.8% | -4.5% | -10.8% | -22.9% | -11.5% | -13.3% | -10.1% |
| ROA | 27.6% | 12.9% | 12.3% | 12.7% | 6.5% | -3.1% | -7.8% | -15.6% | -8.1% | -8.6% | -6.5% |
| Net Profit Margin | 16.4% | 19.9% | 18.6% | 24.1% | 13.7% | -7.8% | -18.2% | -37.1% | -17.8% | -21.2% | -15.1% |
| Debt to Equity | 0.94x | 0.02x | - | 0.11x | 0.15x | 0.16x | 0.15x | 0.13x | 0.09x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Berry Genomics Co Ltd dividends
- Dividend yield
- 0.15%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- May 25, 2001
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 4.73M | 0.01 | - |
| 2024 | CNY 8.69M | 0.02 | - |
| 2023 | CNY 15.5M | 0.04 | - |
| 2022 | CNY 28.3M | 0.09 | - |
| 2021 | CNY 20.3M | 0.06 | - |
| 2020 | CNY 29.2M | 0.08 | 13.9% |
| 2019 | CNY 8.35M | 0.02 | 2.1% |
| 2018 | CNY 762K | 0.00 | 0.3% |
| 2017 | CNY 863K | 0.00 | 0.4% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 13.8:10 on Sep 1, 2006.
Who owns Berry Genomics Co Ltd
- Insiders 20.69%
- Institutions 9.60%
- Public & others 69.72%
- Shares outstanding 354M
- Free float 259M
Berry Genomics Co Ltd company profile
- Company name
- Berry Genomics Co Ltd
- Ticker
- 000710.SHE
- ISIN
- CNE000000PN7
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Apr 2, 1997
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,331
- Fiscal year end
- December
- Address
- Building 5, Beijing, China, 102206
- Phone
- 86 10 5325 9188
- Website
- berrygenomics.com
About Berry Genomics Co Ltd
Berry Genomics Co.,Ltd, a genomics and life science company, develops and commercializes of genetic test technologies in clinical applications in China. The company offers non-invasive DNA prenatal testing service, genetic disease testing, tumor detection, technology services, equipment/reagents, laboratory overall solution, and big data services. It also offers scientific research services and medical testing services and products. In addition, the company provides GENOSi, an intelligent agent cloud platform; and NovaSeq, a next-generation sequencing platform. It serves various organizations and facilities, including hospitals, research institutions, universities, and enterprises throughout Mainland China, Hong Kong, Macau, and Taiwan. The company was founded in 1997 and is headquartered in Beijing, China.
Berry Genomics Co Ltd management
5- Dr. Yang GaoGM & Chairman · born 1980
- Mr. Dong WangCFO, Deputy GM & Director · born 1973
- Mr. Fei XuSecretary to the Board · born 1986
- Dr. Daixing ZhouCo-Founder & Chief Scientist · born 1966
- Li GaoHead of Accounting Department